Cellectis share price rises above €0.94 and rebounds by nearly 16%
The French biotech company is regaining momentum mid-morning, after a session in which it had briefly lost a key threshold. The rebound is supported by preclinical data presented this week in Germany.
A rebound of 15.85% following a test of the €0.94 support level
Cellectis share is trading at €1.13 during the session, up 15.85% compared to the previous day (€0.97), and gaining 15.64% over the week. On Tuesday, the share had broken through its €0.94 support level down to a low of €0.90, before rising back above this threshold.
Today's rebound brings it back above the 20-day moving average (€1.09, a difference of +3.58%), while the 50-day moving average (€1.75) remains well above the current price. This gain does not offset the 56.94% decline suffered over three months, nor the 64.98% decline over one year. The €1.39 resistance level is the next identified level in the data.
Preclinical data on APOC3 gene unveiled in Hamburg
At the European Society of Gene and Cell Therapy (ESGCT) congress, which is being held in Hamburg until October 30, Cellectis presented an expanded set of data on its in vivo base editing candidate targeting the APOC3 gene. In mice, a single administration reduced triglycerides by an average of 75%.
The group is planning a phase 1 trial in China. Cellectis is the only company listed on two markets: the ordinary share, eligible for the PEA, is traded on Euronext Growth Paris, and the ADS on Nasdaq. The CAC 40 is down 0.04% at the same time. Analysts following the stock are grouped on the analyst opinions and consensus page.
